Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate.
about
Pharmacokinetic drug-drug interaction and their implication in clinical managementIdentification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafilClinical relevance of genetic polymorphisms in the human CYP2C subfamilyA single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratioNovel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial.Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavirPharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.Use of antineoplastic agents in patients with cancer who have HIV/AIDS.Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel.Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.Pharmacogenomics of CYP3A: considerations for HIV treatment.Phase I study of nelfinavir in liposarcoma.Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.
P2860
Q27021051-CD538703-4A8D-4961-A4FB-C1B863AA048FQ28362294-EA5FEFE7-5CD8-4719-8784-A4F05ECD1677Q28362533-060C8142-E734-4DCA-A81E-7CF862CFC7D0Q28363552-EC42B4BB-AB07-4002-8AEC-E8CD483B30C6Q30564087-82DECD22-EF79-4D09-8D98-323989913FBFQ33979982-8192F948-EF87-41B8-9AD0-CD6DE1AFDDE2Q34721793-47AAD5B1-7FA4-4097-9F3C-92B3EAFCDA37Q35002453-7DEDD865-116F-4C22-9E16-35066EB43429Q35018246-6CB8504F-A686-442A-8EFB-5C5FEB63A0BDQ35166632-6B04663B-9AF2-43F2-AE96-60326C517F36Q35932561-1F6EEFDA-E15F-48D6-935B-7111AE887065Q36040272-AC4FAC39-7B21-48BB-9B72-6C1721C23B9FQ36320322-3D3B6BEC-5447-4DA8-BEEE-647983B47DEFQ36621462-09A3C029-217B-4939-BB1F-91048FC11F0CQ36637864-1A6DCF9F-DCE6-4669-88A8-E42978C317E6Q37419542-4EB2B1E2-9B4E-47D2-BEDA-F28AA038EF5BQ37523821-E2E5BDFF-DF63-4099-9AD9-412FD2E88EC3Q38882614-6D0E387A-80CF-4598-8760-7FBEA0C2803A
P2860
Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Characterization of the select ...... inhibitor nelfinavir mesylate.
@en
Characterization of the select ...... inhibitor nelfinavir mesylate.
@nl
type
label
Characterization of the select ...... inhibitor nelfinavir mesylate.
@en
Characterization of the select ...... inhibitor nelfinavir mesylate.
@nl
prefLabel
Characterization of the select ...... inhibitor nelfinavir mesylate.
@en
Characterization of the select ...... inhibitor nelfinavir mesylate.
@nl
P2093
P1476
Characterization of the select ...... inhibitor nelfinavir mesylate.
@en
P2093
Lillibridge JH
P304
P577
1998-07-01T00:00:00Z